PolyActiva has recently been awarded a $1.5m CUREator Grant, which will be used to progress its second generation ocular implant as a treatment for patients with glaucoma, targeting sustained daily dosing for 12 months.
PolyActiva reports promising clinical trial results for its 6-month sustained drug delivery, biodegradable ocular implant in glaucoma patients.
The interim Phase 2a results demonstrate a sustained >20% reduction of IOP after 6 months with a favorable safety profile.
PolyActiva presents positive clinical trial results at the 2022 American Glaucoma Society Annual Meeting – March 2022
PolyActiva successfully completes initial clinical trial with Latanoprost FA SR Ocular Implant delivering glaucoma treatment to patients over a six-month period.
PolyActiva appoints Tracy Valorie, ophthalmic industry expert and former Bausch + Lomb executive, to its Board of Directors.
PolyActiva completes recruitment in key Phase I glaucoma implant safety study. Six-month treatment period demonstrated.
© 2023 PolyActiva. All Rights Reserved. Caution: PolyActiva products are not for sale in the US